Findings

What do systematic reviews say?

52 questions · 52 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 8 · 15.4%GRADE not reported 5 · 9.6%Very low 2 · 3.8%Low 7 · 13.5%Moderate 24 · 46.2%High 6 · 11.5%

Intervention not reported

ACQ responders at 6 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 3063(3 RCTs)

The intervention showed no clear difference in ACQ responders at 6 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of… (low certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.09 [0.99, 1.19]
3 studies · 6 participants
Low

Intervention not reported

ACQ responders at 6 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 1916(2 RCTs)

It is very uncertain whether the intervention changes ACQ responders at 6 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of… (very low certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.11 [0.91, 1.35]
2 studies · 6 participants
Very low

Intervention not reported

ACQ responders at 12 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 1088(1 RCT)

The intervention probably leads to higher ACQ responders at 12 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.08 [1.01, 1.15]
1 study · 12 participants
Moderate

Intervention not reported

CFB in AQLQ at 12 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 2815(2 RCTs)

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 12 participants
Moderate

Intervention not reported

ACQ responders at 12 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 2222(2 RCTs)

The intervention showed no clear difference in ACQ responders at 12 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.01 [0.95, 1.07]
2 studies · 12 participants
Moderate

Intervention not reported

ACQ responders at 6 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 3700(3 RCTs)

The intervention showed no clear difference in ACQ responders at 6 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 1.02 [0.96, 1.08]
3 studies · 6 participants
Moderate

Intervention not reported

ACQ responders at 12 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 2817(2 RCTs)

The intervention showed no clear difference in ACQ responders at 12 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of… (low certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 0.99 [0.9, 1.07]
2 studies · 12 participants
Low

Intervention not reported

Dropouts due to adverse event ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 3205(3 RCTs)

It is very uncertain whether the intervention changes dropouts due to adverse event ‐ MD TRIPLE vs MD‐ICS/LABA№ of… (very low certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 0.42 [0.08, 2.14]
3 studies · 3205 participants
Very low

Intervention not reported

Dropouts due to adverse event ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 2670(2 RCTs)

The intervention showed no clear difference in dropouts due to adverse event ‐ HD TRIPLE vs MD‐ICS/LABA№ of… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 0.47 [0.19, 1.18]
2 studies · 2670 participants
Moderate

Intervention not reported

Moderate to severe exacerbations ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 3184(3 RCTs)

The intervention probably leads to lower moderate to severe exacerbations ‐ MD TRIPLE vs MD‐ICS/LABA№ of… (moderate certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 0.86 [0.75, 0.99]
3 studies · 3184 participants
Moderate

Intervention not reported

Moderate to severe exacerbations ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 2037(2 RCTs)

The intervention leads to lower moderate to severe exacerbations ‐ HD TRIPLE vs MD‐ICS/LABA№ of… (high certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 0.78 [0.66, 0.92]
2 studies · 2037 participants
High

Intervention not reported

Moderate to severe exacerbations ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 5452(6 RCTs)

The intervention showed no clear difference in moderate to severe exacerbations ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of… (high certainty).

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
RR 0.93 [0.82, 1.05]
6 studies · 5452 participants
High